Asset profile
Verteporfin
Small molecule
Evidence outlook
Approved: Age-Related Macular Degeneration
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
31 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 31 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Verteporfin: this drug | Approved | Small molecule | Benzoporphyrin-derivative photosensitizer for photodynamic therapy | ||
| Aflibercept (Eylea) | Approved | Protein / enzyme therapeutic | VEGF-A, VEGF-A / VEGF-B / Placental Growth Factor (PlGF) | ||
| Avacincaptad Pegol (Izervay) | Approved | Rna Aptamer | Complement C5 | ||
| Brolucizumab-Dbll | Approved | Monoclonal antibody | VEGF-A | ||
| Chloroprocaine | Approved | Small molecule | Voltage-gated sodium channels (Nav) on sensory nerve membranes | ||
| Faricimab | Approved | Multispecific antibody | Angiopoietin-2 / VEGF-A | ||
| Pegaptanib (Macugen) | Approved | Small molecule | VEGF-A | ||
| Pegcetacoplan Ophthalmic (Syfovre) | Approved | Peptide | Complement C3, Complement C3 / C3b | ||
| Ranibizumab (Lucentis) | Approved | Monoclonal antibody | VEGF-A | ||
| Visudyne | Approved | Small molecule | Photosensitizing agent (photodynamic therapy) | ||
| ABBV-RGX-314 | Phase 3 | Gene therapy / editing | VEGF-A | ||
| ABP 938 | Phase 3 | Protein / enzyme therapeutic | VEGF-A / VEGF-B / PlGF | ||
| ANX007 | Phase 3 | Monoclonal antibody | Complement C1q | ||
| Cemdisiran | Phase 3 | RNA / oligonucleotide | Complement C5 | ||
| CKD-701 | Phase 3 | Monoclonal antibody | VEGF-A | ||
| HLX04-O | Phase 3 | Monoclonal antibody | VEGF-A |
…and 16 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
July 2027 (1)
What to watch
2028 (3)
January 2028 (1)
What to watch
February 2028 (1)
What to watch
March 2028 (1)
What to watch
2029 (1)
October 2029 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.